Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01309074

Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Rush University Medical Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to compare the safety \& efficacy of sertraline (up to a dose of 200mg/day) \& pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety in patients with epilepsy.

Detailed description

Patients with epilepsy will be treated with either sertraline (up to a dose of 200mg/day) or pregabalin (up to a dose of 300mg/day) for the treatment of symptoms of anxiety. Outcome measures will include changes in the anxiety severity scales.

Conditions

Interventions

TypeNameDescription
DRUGPregabalin-LyricaPregabalin in a dose up to 300mg/day in BID dosing.
DRUGSertralineSertraline in a dose up to 200mg/day in BID dosing.

Timeline

Start date
2009-11-01
Primary completion
2012-12-01
Completion
2012-12-01
First posted
2011-03-04
Last updated
2023-02-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01309074. Inclusion in this directory is not an endorsement.